Obesity

GLP-1 receptor agonist use on top of SGLT2 inhibition in patients with HF with preserved ejection fraction, type 2 diabetes and obesity was associated with reduced risk for adverse events vs. SGLT2 inhibition alone, researchers reported.

Analyses of people with early-onset colorectal cancer showed those who lived in rural areas had greater 5-year disease-related mortality risk than those who lived in nonrural areas, according to results of a retrospective study.

Gaining weight can raise the risk for atopic dermatitis and possibly other immune-mediated skin diseases in children, whereas losing weight can reduce this risk, according to a study.

Adults with obesity who have been prescribed tirzepatide can now purchase 2.5 mg and 5 mg single-dose vials of the medication, Eli Lilly announced.

Adults who take semaglutide may have increased risk for developing suicidal thoughts, according to results from a case-control study published in JAMA Network Open.

A majority of people with diabetes rely on their primary care provider for diabetes management and believe using drugs such as GLP-1 receptor agonists are enough to manage their disease, according to survey results.

A novel prognostic model identified risk factors including smoking, obesity, HbA1c and albuminuria as significant predictors of incident heart failure risk among Native American adults, researchers reported.

Adults with prediabetes and overweight or obesity have a 94% lower risk for developing type 2 diabetes with the once-weekly GIP/GLP-1 dual agonist tirzepatide vs. placebo, according to top-line results from the SURMOUNT-1 3-year study.

Twelve circulating proteins associated with obesity and heart failure may inform treatment for adults with both conditions, according to a study published in Obesity.

Women with vs. without intellectual and developmental disabilities have greater risks for stillbirth and other adverse obstetric, mental health and medical outcomes, according to findings published in JAMA Network Open.